The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Fri., Dec. 14, 8:25 AM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #31. Actavis Four Products from Akorn

Acquirer: Actavis (NASDAQ:ACT)
Acquiree: Four Products from Akorn
Details: Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

Actavis is a pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. Co. also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. Co. has three reporting segments which includes Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. As of Dec 31 2013, Co.'s portfolio included approximately 250 generic pharmaceutical product families and approximately 45 brand pharmaceutical product families.

Preferred: ACT.PRA



Open the ACT Page at The Online Investor »

Company Name: 
Allergan PLC
Website: 
www.actavis.com
Sector: 
Drugs & Pharmaceuticals
 

Open the ACT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.78 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 31 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2018, All Rights Reserved Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.